11hb: Difference between revisions
From Proteopedia
Jump to navigationJump to search
m Protected "11hb": Seeded page ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)) |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Crystal structure of a GII.4 norovirus capsid P domain in complex with neutralizing antibody 17A5== | |||
<StructureSection load='11hb' size='340' side='right'caption='[[11hb]], [[Resolution|resolution]] 3.36Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[11hb]] is a 9 chain structure with sequence from [https://en.wikipedia.org/wiki/Mus_musculus Mus musculus] and [https://en.wikipedia.org/wiki/Norovirus_GII.4_Sydney_2012 Norovirus GII.4 Sydney 2012]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=11HB OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=11HB FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 3.36Å</td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=11hb FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=11hb OCA], [https://pdbe.org/11hb PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=11hb RCSB], [https://www.ebi.ac.uk/pdbsum/11hb PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=11hb ProSAT]</span></td></tr> | |||
</table> | |||
== Function == | |||
[https://www.uniprot.org/uniprot/A0A1P8DD09_NORV A0A1P8DD09_NORV] | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Noroviruses are a leading cause of acute gastroenteritis worldwide, yet no licensed vaccines or antivirals are available. A major barrier to broadly protective vaccine development is the extensive genetic and antigenic diversity of these viruses, leading to immune escape. However, the structural mechanisms underlying this immune escape remain incompletely defined. Here, we analyze a panel of monoclonal antibodies generated against a pandemic GII.4 variant to define the molecular determinants of neutralizing immunity. Guided by immunogenetic features and cross-reactivity patterns spanning four decades of viral evolution, we resolved the atomic structures of two neutralizing antibodies targeting the principal immunodominant antigenic sites, A and G. We show that the spatial positioning of antigenic site G shapes neutralizing responses and that coordinated substitutions within these epitopes drove the rapid antigenic transitions observed between 2004 and 2012.Together, these findings establish a structural framework for GII.4 antigenic evolution and inform rational vaccine design. | |||
Structural and genetic analysis of neutralizing antibodies reveals mechanisms of GII.4 norovirus antigenic evolution.,Parra G, Pilewski K, Ghosh A, Tohma K, Ford-Siltz L, Hernandez A, Pajuelo M, Landivar M, DuBois R Res Sq [Preprint]. 2026 Mar 31:rs.3.rs-9077120. doi: 10.21203/rs.3.rs-9077120/v1. PMID:41960338<ref>PMID:41960338</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
<div class="pdbe-citations 11hb" style="background-color:#fffaf0;"></div> | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Large Structures]] | |||
[[Category: Mus musculus]] | |||
[[Category: Norovirus GII 4 Sydney 2012]] | |||
[[Category: DuBois RM]] | |||
[[Category: Ghosh A]] | |||